Estimates Revisions Exelixis, Inc. Sao Paulo
Stocks
E2XE34
BRE2XEBDR001
Biotechnology & Medical Research
|
Market Closed -
Sao Paulo
09:00:00 2026-08-19 EDT
|
5-day change | 1st Jan Change | ||
| 138.00 BRL | -0.22% |
|
+4.59% | +14.89% |
| 08-05 | Exelixis, Inc., Q2 2026 Earnings Call, Aug 05, 2026 | |
| 08-05 | (EXEL) Exelixis Now Expects Fiscal 2026 Revenue Range $2.50B-$2.55B, vs. FactSet Est of $2.60B | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- EXEL Stock
- E2XE34 Stock
- Consensus Exelixis, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
